陽光諾和(688621.SH):擬註銷控股孫公司諾和欣
格隆匯5月12日丨陽光諾和(688621.SH)公佈,公司於2025年5月12日召開第二屆董事會第十九次會議,審議通過了《關於註銷孫公司南京諾和欣醫藥科技有限公司暨關聯交易的議案》,同意註銷控股孫公司諾和欣。根據《中華人民共和國公司法》《北京陽光諾和藥物研究股份有限公司公司章程》等相關規定,根據公司的發展規劃以及孫公司實際運營情況,為進一步優化內部管理結構,減少法人層級,降低運營成本,提高整體運營效率及經營效益,降低經營管理成本,經公司審慎研究,經過審慎考慮公司擬註銷控股孫公司諾和欣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.